Search results for "BTLA"

showing 1 items of 1 documents

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma

2019

PDAC is one of the most heterogeneous cancers with low chemotherapeutic sensitivity due to a dense stroma, a weak vasculature and significant biological aggressivity. In cancer, suppressive immune checkpoints are often hyper-activated to ensure an effective evasion of tumor cells from immune surveillance. These immune checkpoints include in part, the B7/butyrophilin-like receptors such as butyrophilin sub-family 3A/CD277 receptors (BTN3A), the B and T lymphocyte attenuator (BTLA) belonging to the B7-like receptors and the programmed death protein (PD-1) with its ligand PD-L1. We evaluated the plasma level of these markers in 32 PDAC patients (learning cohort) by ad hoc developed ELISA’s and…

0301 basic medicinelcsh:Immunologic diseases. Allergybutyrophilin 3Aendocrine system diseases[SDV]Life Sciences [q-bio]Immunologypancreatic cancerBTLA[SDV.CAN]Life Sciences [q-bio]/Cancerprogrammed cell death-1B and T lymphocyte attenuatorlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemStromaPancreatic cancerPD-L1medicineImmunology and Allergyprogrammed cell death ligand-1Original Researchbiologybusiness.industryCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesImmune checkpoint3. Good health030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbiology.proteinoutcomeAdenocarcinomaImmune checkpointbusinesslcsh:RC581-607[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct